Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

July 28, 2020July 28, 2020

CAR T-cell Therapy Tecartus Granted FDA Approval for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Kite Pharma’s CAR T-cell therapy Tecartus (brexucabtagene autoleucel) for adults with relapsed or refractory mantle cell lymphoma (MCL). The ... Read more

July 20, 2020July 20, 2020

Imfinzi Plus Chemo Aids Survival in Inoperable Pleural Mesothelioma, Phase 2 Data Show

News

Adding Imfinzi (durvalumab) to standard first-line chemotherapy prolongs survival for adults newly diagnosed with inoperable malignant pleural mesothelioma, according to data from a Phase 2 clinical trial. This study is ... Read more

July 6, 2020July 6, 2020

First-line Tislelizumab Plus Chemo Under Review in China for Advanced NSCLC

News

The Chinese Center for Drug Evaluation (CDE) of the National Medical Products Administration has accepted for review Beigene’s application seeking approval for tislelizumab, in combination with standard chemotherapy, as a first-line treatment ... Read more

June 18, 2020June 18, 2020

Keytruda Approved to Treat Solid Tumors With High Mutational Burden

News

The U.S. Food and Drug Administration (FDA) has conditionally approved Keytruda (pembrolizumab) for the treatment of pediatric and adult patients with inoperable or metastatic solid tumors with high tumor ... Read more

June 17, 2020June 17, 2020

Bavencio Shows Benefit as 1st-line Maintenance Therapy for Bladder Cancer in Phase 3 Trial

News

First-line maintenance therapy with Bavencio (avelumab) significantly delays disease progression or death in people with inoperable, locally advanced or metastatic urothelial carcinoma, a common type of bladder cancer, according to interim data ... Read more

March 23, 2020March 23, 2020

Better Responses with IO102-Keytruda Combo Likely in Ongoing NSCLC Trial

News

Adding IO Biotech’s lead candidate, IO102, to first-line treatment with Keytruda (pembrolizumab) is likely to result in better response rates in people with metastatic non-small cell lung cancer (NSCLC), an interim ... Read more

March 20, 2020March 20, 2020

Harbour BioMed Gets FDA Nod to Start US Trials of 2 Immunotherapies

News

The U.S. Food and Drug Administration (FDA) has approved Harbour BioMed’s investigational new drug applications to initiate U.S. clinical trials testing two of its immunotherapy candidates — HBM9167 and HBM4003 — ... Read more

March 6, 2020March 6, 2020

Cabiralizumab Plus Opdivo Failed to Halt Progression of Advanced Pancreatic Cancer, Trial Shows

News

Combining Five Prime Therapeutics‘ investigational therapy cabiralizumab with Opdivo (nivolumab) — with and without chemotherapy — failed to halt disease progression in people with advanced pancreatic cancer, compared with ... Read more

December 13, 2019

Bemcentinib-Keytruda Combo Effective in Some Advanced NSCLC Patients with Poor Prognosis

News

Combining bemcentinib with Keytruda (pembrolizumab) is effective and delays disease progression in people with previously treated advanced non-small cell lung cancer (NSCLC), particularly in those with AXL-positive tumors. Those updated results from a Phase 2 ... Read more

November 11, 2019

2 Imfinzi Combos Delay Cancer Progression in Metastatic NSCLC, Interim Phase 3 Data Show

News

Adding Imfinzi (durvalumab) — alone or in combination with tremelimumab — to standard first-line chemotherapy significantly delayed disease progression or death in people with metastatic non-small cell lung cancer (NSCLC), compared ... Read more

Pin It on Pinterest